The alliance will pair EVERSANA's NAVLIN platform, which provides data and information on global pricing and market access, ...

As recent advances in small molecules, ADCs, cell, and gene therapies poise novel precision therapies from the bench to the ...

At JP Morgan Week 2025, pharmaphorum’s Jonah Comstock took a quick detour to Grove.AI’s San Francisco offices to talk to ...

Artificial intelligence startup Quibim has raised $50 million in first-round financing to support the rollout of its ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Digital tools, powered by intuitive design, AI, and customer centricity, offer a unique opportunity to bridge the trust gap ...

Over 6.3 million patients make up the NHS backlog for consultant-led elective care, which reached 7,573,212 in September 2024 ...

AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster drug as a second-line treatment for patients with HER2-low and ...

The scale of the decline in Veru's shares despite the positive result may reflect the amplified expectations of investors for ...

Since then, Biogen decided to opt out of their partnership on essential tremor candidate SAGE-324 after disappointing results ...

The word on San Francisco’s famously hilly streets is that big pharma is ready to go shopping in 2025, following a flurry of ...

The pharma group has pledged up to £50 million ($62.5 million) in funding over three years for the initiative, which builds ...